Results 181 to 190 of about 17,905 (230)

Micafungin

Annals of Pharmacotherapy, 2004
OBJECTIVE To review the pharmacology, mycology, chemistry, in vitro susceptibility, pharmacokinetics, clinical efficacy, safety, tolerability, dosage, and administration of micafungin, an echinocandin antifungal agent. DATA SOURCES A MEDLINE search, restricted to English language, was conducted from 1978 to November 2003. Supplementary sources included
Blair, Jarvis, David P, Figgitt, Lesley J, Scott   +2 more
  +7 more sources

Micafungin

Reactions Weekly, 2018
Nessuno
Beyda ND, Lewis RE, Kontoyiannis DP
  +8 more sources

Micafungin: A promising inhibitor of UBE2M in cancer cell growth suppression.

European journal of medicinal chemistry, 2023
Neddylation is a protein modification process similar to ubiquitination, carried out through a series of activating (E1), conjugating (E2), and ligating (E3) enzymes.
M. Mamun, Shuan Liu, Li-Juan Zhao, Lijuan Zhao, Zhong-Rui Li, Dandan Shen, Yu Zheng, Yichao Zheng, Hongmin Liu   +8 more
semanticscholar   +1 more source

Risk assessment of micafungin-induced liver injury using spontaneous reporting system data and electronic medical records.

Journal of Infection and Chemotherapy, 2022
INTRODUCTION There is limited information regarding antifungal-induced liver injuries, which have high mortality rates. Therefore, we used the Japanese Adverse Drug Event Report (JADER) database for signal detection associated with antifungal-induced ...
Yuki Asai, Takanori Yamamoto, Yoshiharu Sato   +2 more
semanticscholar   +1 more source

An overview of micafungin as a treatment option for invasive candidiasis in pediatric patients younger than 4 months old

Expert Opinion on Pharmacotherapy, 2022
Introduction Invasive candidiasis remains a leading cause of morbidity and mortality in various categories of patients at risk. Areas covered Structure and mechanism of action, pharmacokinetics and pharmacodynamics, clinical studies, safety, and ...
M. Bassetti, D. Giacobbe, A. Vena, S. Esposito   +3 more
semanticscholar   +1 more source

Micafungin

Drugs, 2012
exaly   +4 more sources

Evaluation of the Post‐Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata

Mycoses (Berlin), 2022
Rezafungin, a new echinocandin with an extended half‐life, exhibits potent activity against Candida spp. Aside from the MIC, specific interactions between antifungal and isolate, including the duration of anti‐infective activity, may impact dose interval
C. Carvalhaes, P. Rhomberg, M. Pfaller, J. B. Locke, M. Castanheira   +4 more
semanticscholar   +1 more source

Antimicrobial photodynamic therapy for oral candidiasis not responsive to micafungin in a patient undergoing hematopoietic cell transplantation.

Photodiagnosis and Photodynamic Therapy, 2021
In hematopoietic cell transplants (HCT) patients, opportunistic fungal infections - especially candidiasis - are typical and, due to the immunosuppressed condition, severe and fatal clinical conditions may occur.
L. Campos, S. B. Rezende, L. Palma, Andressa Matucci Hotsumi, Ricardo Yudi Tateno, A. Simões, L. Y. Okada, M. Macedo   +7 more
semanticscholar   +1 more source

Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?

Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND Echinocandin resistance rarely occurs in clinical Candida parapsilosis isolates and the underlying mechanism is unknown. OBJECTIVES To determine the prevalence of echinocandin resistance and the underlying mechanism for a large collection of
A. Arastehfar, F. Daneshnia, S. Hilmioğlu-Polat, M. Ilkit, Melike Yaşar, Furkan Polat, D. Metin, Ülküm Zafer Dokumcu, W. Pan, F. Hagen, T. Boekhout, D. Perlin, C. Lass‐Flörl   +12 more
semanticscholar   +1 more source